Clinical trials: Outpatient Treatment
Migraine Headache
MK0462 in Treatment of Migraine With Recurrence (MK0462-022)
A study to evaluate rizatriptan/MK0462 (5 and 10 mg) for the treatment of acute migraine attack and treatment of up to two headache recurrences compared to placebo.
- Trial name
- NCT00897949
- Testing
- rizatriptan benzoate (MK0462)
- Volunteers
- 1,473 people
- Sponsor
- Organon and Co
Restless Legs Syndrome
Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients
To evaluate safety and efficacy of pramipexole in the treatment of patients suffering from moderate to severe RLS over 6 weeks under double blinded conditions followed by a 46 week open label or double blind extension.
- Trial name
- NCT00275457
- Testing
- pramipexole
- Where
- 34 sites in Austria, Germany and 3 more
- Volunteers
- 346 people
- Sponsor
- Boehringer Ingelheim
Major Depressive Disorder
Study Evaluating DVS-233 for Treatment of Outpatients With Major Depressive Disorder
To evaluate the long-term safety of desvenlafaxine sustained release (DVS-233SR) during open-label treatment of outpatients with major depressive disorder (MDD).
- Trial name
- NCT00452595
- Testing
- DVS-233 SR (desvenlafaxine sustained release )
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Hypertension, Pulmonary
Rapid Switch From Flolan to Remodulin in the Outpatient Clinic
The purpose of this 8-week study is to compare the effects of switching from therapy with epoprostenol or Flolan to IV Remodulin.
- Trial name
- NCT00643604
- Testing
- treprostinil sodium
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- United Therapeutics
Irritable Bowel Syndrome
Safety and Therapeutic Efficacy of Phosphate Enema (Kleen Enema) in Patients Undergoing Sigmoidoscopy
The Purpose of the study is to determine the efficacy of Kleen Enema® (Phosphate Enema) for bowel preparation in out-patients under going sigmoidoscopy procedure and to evaluate the safety behavior of Kleen Enema® in outpatients…
- Trial name
- NCT02386904
- Testing
- Phosphate Enema (Kleen® Enema)
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- Nabiqasim Industries (Pvt) Ltd
Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis
Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection
This is a Phase 1b/2a study with the primary objective to determine if BX004-A is safe and tolerable. Exploratory objectives include whether BX004-A reduces sputum Pseudomonas aeruginosa (PsA) bacterial load in CF subjects with…
- Trial name
- NCT05010577
- Testing
- BX004-A
- Where
- 28 sites in United States, Czechia and 3 more
- Volunteers
- 43 people
- Sponsor
- BiomX, Inc.
Insomnia
Fifty Two Week Extension Trial of Org 50081 (Esmirtazapine) in the Treatment of Insomnia (P05708)
This trial is a 52-week, open-label extension trial to investigate safety and to explore efficacy of Org 50081 (Esmirtazapine) in participants who completed Protocol 176001 (P05706) (NCT00482612) or 176002 (P05707) (NCT00506389).
- Trial name
- NCT00610675
- Testing
- Org 50081
- Volunteers
- 346 people
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19
Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19
This exploratory study is a randomized, single center, open label study of four different experimental treatment arms versus standard of care for the treatment of SARS-CoV-2 infection in symptomatic outpatients with mild disease…
- Trial name
- NCT04532931
- Testing
- Paracetamol, Artesunate-amodiaquine, Pyronaridine-artesunate
- Where
- South Africa
- Volunteers
- 192 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Generalized Anxiety Disorder
Treatment of Patients With Anxiety Disorder (0777-022)
The purpose of the study is to examine the safety and efficacy of MK0777 during treatment for Generalized Anxiety Disorder.
- Trial name
- NCT00539578
- Testing
- MK0777
- Volunteers
- 270 people
- Sponsor
- Merck Sharp & Dohme LLC
Stage II Peripheral Arterial Occlusive Disease, Intermittent Claudication Fontaine Stage II PAOD
Prostaglandin E1 in Outpatients With Intermittent Claudication
Investigate, under outpatient conditions, both the effect of 4 weeks of daily treatment with Prostaglandin E1 and that of 4 weeks of interval treatment (two infusions per week) on the pain-free walking distance in patients with…
- Trial name
- NCT01263925
- Testing
- Alprostadil (Prostaglandin E1), Pentoxifylline
- Where
- 36 sites in Germany
- Volunteers
- 561 people
- Sponsor
- UCB Pharma
Schizophrenic Disorders
Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone
The trial is designed to assess the long term subjective well-being in schizophrenic outpatients treated with quetiapine XR (extended release) or oral risperidone at flexible dose in a naturalistic setting over a period of one…
- Trial name
- RECOVER (NCT00600756)
- Testing
- Quetiapine XR, Risperidone
- Where
- 116 sites in Belgium, Brazil and 12 more
- Volunteers
- 798 people
- Sponsor
- AstraZeneca
Depressive Disorder
A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression
The primary objective is to evaluate the safety and tolerability of abrupt discontinuation of saredutant over 1 week in outpatients with depression who completed 8 weeks of treatment with saredutant 100 mg once daily.
- Trial name
- NCT00429260
- Testing
- Saredutant
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Sanofi
Participants Less Than 12 Months of Age With RSV Illness
A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness
This was a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to determine the effect of a single 30 mg/kg intramuscular (IM) dose of motavizumab on viral load and motavizumab levels in the upper respiratory…
- Trial name
- NCT00435227
- Testing
- Motavizumab
- Where
- 31 sites in United States
- Volunteers
- 12 people
- Sponsor
- MedImmune LLC
Insomnia
An Exploratory Study of NBI-34060 Capsules and Next Day Functioning
NBI-34060 is an investigational (research) medication being studied in people with insomnia. The current study is designed to evaluate how people, who experience a nighttime awakening with difficulty returning to sleep, feel…
- Trial name
- NCT00525941
- Testing
- NBI-34060
- Where
- 4 sites in United States
- Sponsor
- Neurocrine Biosciences
Alcoholism
Clinical Study of TripleA for Treatment of Alcohol Addiction in Outpatient Care
The primary objective is to investigate differences in the alcohol consumption pattern between alcohol addicts receiving conventional treatment and those who receive a combination of conventional treatment and TripleA.
- Trial name
- NCT03195894
- Testing
- TripleA
- Volunteers
- 115 people
- Sponsor
- Kontigo Care AB
Efficacy and Safety
Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness
The purpose of this study is to assess the efficacy and safety of Proxalutamide (GT0918) as a treatment for outpatients COVID-19 subjects.
- Trial name
- NCT04870606
- Testing
- Proxalutamide (GT0918)
- Where
- 8 sites in United States
- Volunteers
- 733 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Prostate Cancer
Phase II Laser Focal Therapy of Prostate Cancer
Target recruitment: 1000 subjects. The purpose of this research study is to continue to investigate the safety and effectiveness of using MR (magnetic resonance) guided laser focal therapy for prostate cancer and to evaluate…
- Trial name
- LITT or FLA (NCT02243033)
- Testing
- MR-guided laser focal therapy
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- HALO Diagnostics
Epilepsy, Major Depressive Disorder (MDD)
Lethargic Depression Study
This is a study of Major Depressive Disorder (MDD) in patients with decreased energy, pleasure and interests.
- Trial name
- NCT00064467
- Testing
- Extended-release bupropion (HCl)
- Where
- 24 sites in United States
- Volunteers
- 268 people
- Sponsor
- GlaxoSmithKline
Cognitive Dysfunction, Schizophrenia
TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia
Schizophrenia affects approximately 1% of the population worldwide, and in about 80% of cases, it is a lifelong, disabling illness.
- Trial name
- NCT01003379
- Testing
- TC-5619
- Where
- 16 sites in United States, India
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Targacept Inc.
Pulmonary Disease, Chronic Obstructive
Danish Quality Assurance Project on Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (COPD) in Outpatient Lung Clinics
Danish Quality Assurance Project on Diagnosis and Treatment of COPD in Outpatient Lung Clinics
- Trial name
- NCT00268866
- Testing
- Education
- Volunteers
- 1,820 people
- Sponsor
- Boehringer Ingelheim